Clinical utility of existing and second-generation interferon-γ release assays for diagnostic evaluation of tuberculosis: an observational cohort study by Whitworth, Hilary S. et al.
Kent Academic Repository
Full text document (pdf)
Copyright & reuse
Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all
content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions 
for further reuse of content should be sought from the publisher, author or other copyright holder. 
Versions of research
The version in the Kent Academic Repository may differ from the final published version. 
Users are advised to check http://kar.kent.ac.uk for the status of the paper. Users should always cite the 
published version of record.
Enquiries
For any further enquiries regarding the licence status of this document, please contact: 
researchsupport@kent.ac.uk
If you believe this document infringes copyright then please contact the KAR admin team with the take-down 
information provided at http://kar.kent.ac.uk/contact.html
Citation for published version
Whitworth, Hilary S and Badhan, Amarjit and Boakye, Aime A and Takwoingi, Yemisi and Rees-Roberts,
Melanie and Partlett, Christopher and Lambie, Heather and Innes, John and Cooke, Graham and
Lipman, Marc and Conlon, Christopher and Macallan, Derek and Chua, Felix and Post, Frank
A and Wiselka, Martin and Woltmann, Gerrit and Deeks, Jonathan J and Kon, Onn Min and Lalvani,
DOI
https://doi.org/10.1016/S1473-3099(18)30613-3





TITLE: An observational cohort study to evaluate the clinical utility of current and 




Hilary S Whitworth (PhD),1,2 Amarjit Badhan (MSc),*1,3 Aime A Boakye (MSc),*1,3 Yemisi 
Takwoingi (PhD),*4 Melanie Rees-Roberts (PhD),*1,3,5 Christopher Partlett (PhD),4 Heather 
Lambie (MSc Hons.),1 Professor John Innes (FRCP),6 Professor Graham Cooke (DPhil),7 Marc 
Lipman (MD),8,9 Professor Christopher Conlon (MD),10 Professor Derek Macallan (PhD),11 
Felix Chua (PhD),11 Professor Frank Post (PhD),12 Professor Martin Wiselka (PhD),13 Gerrit 
Woltmann (MD),14 Professor Jonathan J Deeks (PhD),4 Professor Onn Min Kon (MD)#1,3,7 and 
Professor Ajit Lalvani (DM)#1,3 on behalf of the IGRAs for Diagnostic Evaluation of Active 
TB (IDEA) Study Group. 
 
1Tuberculosis Research Centre, National Heart and Lung Institute, Imperial College London, 
St Mary's Campus, Norfolk Place, London W2 1PG. 
2Department of Clinical Research, London School of Hygiene and Tropical Medicine, Keppel 
Street, London WC1E 7HT. 
3NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London, 
St Mary's Campus, Norfolk Place, London W2 1PG. 
4Institute of Applied Health Research, Public Health Building, University of Birmingham, 
Birmingham B15 2TT. 
5Centre for Health Services Studies, University of Kent, Canterbury, CT2 7NZ. 
6Heart of England NHS Foundation Trust. Bordesley Green East, Birmingham B9 5SS. 
7St Mary’s Hospital, Imperial College Healthcare Trust, Praed Street, London W2 1NY. 
2 
8Royal Free London NHS Foundation Trust, Pond Street, London NW3 2QG. 
9University College London (UCL) Respiratory, Division of Medicine, UCL, London. 
10Oxford University Hospitals NHS Trust, Oxford, OX3 9DU. 
11St George’s Healthcare NHS Trust, Cranmer Terrace, London SW17 0RE. 
12King’s College Healthcare NHS Trust, Cutcombe Road, London SE9 5RJ. 
13
 Department of Infection and Tropical Medicine. University Hospitals of Leicester NHS 
Trust. Leicester LE1 5WW. 
14Respiratory Biomedical Research Centre, Institute for Lung Health, Department of Infection, 
Immunity and Inflammation, University of Leicester, Leicester LE3 9QP, UK. 
 
*These four authors contributed equally to this work. 
#These two authors contributed equally to this work. 
 
Corresponding author: Professor Ajit Lalvani 
Address - Director, Tuberculosis Research Centre, National Heart and Lung Institute, 
Imperial College London, St Mary's Campus, Norfolk Place, London W2 1PG. 
Email - a.lalvani@imperial.ac.uk  









RESEARCH IN CONTEXT  
Evidence before study 
Although the role of IGRAs in diagnosis of active TB is unclear, their use in clinical practice 
is common. A comprehensive systematic review and meta-analysis published in 2011 describes 
data from studies evaluating diagnostic accuracy of IGRAs in active TB up to November 2009. 
We therefore searched PubMed for original research studies published in any language between 
December 2009 and June 2018, using search terms for tuberculosis AND interferon gamma 
release assays, T-SPOT.TB or Quantiferon AND diagnosis, evaluation, rule-in or rule-out. The 
evidence-base to-date suggests that current IGRAs have insufficient specificity to rule in TB 
and insufficient sensitivity to rule out TB. However, this is derived primarily from studies that 
are either small, low quality, or not representative of patient populations seen in real-life 
clinical practice. Only one large prospective cohort study embedded in routine practice was 
identified, but in a high TB-incidence setting. Thus, fifteen years after introduction of IGRAs, 
the ability of policy-makers in low TB-incidence settings to generate recommendations and 
guidelines for the role of IGRAs in active TB is still hampered by a paucity of reliable and 
informative evidence.   
Added value of this study 
This is the largest prospective study specifically to define the role of IGRAs in diagnosis of 
active TB in a low TB incidence setting. Because the study was multicentre and embedded in 
routine clinical practice in England, and recruited patients representing the full natural clinical 
spectrum of TB, the results are generalisable to other high income, low incidence settings. By 
demonstrating that existing IGRAs have no useful role in diagnosis of active TB, it resolves a 
major clinical uncertainty and represents a significant new high-quality component of the 
evidence-base. Simultaneous evaluation of second-generation IGRA identifies this as a 
potentially useful high-sensitivity triage test that meets a major unmet clinical need. 
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Implications of all the available evidence 
Results from this and previous studies can now be used to generate evidence-based national 
guidelines and recommendations for TB diagnosis. Specifically, neither T-SPOT.TB nor QFT-
GIT have sufficient sensitivity or negative predictive value (NPV) to rule out a diagnosis of 
TB. Taken together with their low specificity and consequent inability to rule in a diagnosis of 
TB, existing IGRAs do not have a clinically useful role in the diagnostic work-up of TB. The 
finding that the second-generation IGRA may have sufficiently high sensitivity, low negative 
likelihood ratio and high NPV to serve as a triage test to help rule-out a diagnosis of TB within 
24 hours indicates a clinically useful role for this novel test and provides the basis for evidence-




















The role of interferon-gamma release assays (IGRAs) in diagnosis of active tuberculosis (TB) 
is unclear, yet they are commonly used in low-TB-incidence countries. This study sought to 
resolve this clinical uncertainty by determining the diagnostic accuracy and role of current and 
second-generation IGRAs in the diagnostic assessment of suspected TB in a low-incidence 
setting.  
Methods 
This was a prospective cohort study of 1,060 adults with suspected TB, conducted in routine 
secondary care in England. Patients were tested for M. tuberculosis (Mtb) infection at baseline 
using current and second-generation IGRAs, the latter incorporating novel Mtb antigens, and 
followed up for 6-12m to establish definitive diagnoses. Sensitivity, specificity and positive 
and negative likelihood ratios (LRs) and predictive values (PVs) of the tests for TB were 
determined. 
Findings 
TB was diagnosed in 363 (43%) of 845 patients included in analyses. Sensitivity of T-
SPOT.TB was 81.4% (95%CI 76.6-85.3%), higher than Quantiferon-Gold In-Tube at 67.3% 
(95%CI 62.0-72.1%). Second-generation IGRA had higher sensitivity than current tests, at 
94.0% (95%CI 90.0–96.4%) for culture-confirmed TB and 89.2% (95%CI 85.2–92.2%) when 
including highly-probable TB, giving a negative LR for all TB of 0.13 (95%CI 0.10-0.19). 
Specificity ranged from 86.2% (95%CI 82.3-89.4%) for T-SPOT.TB to 80.0% (95%CI 75.6-
83.8%) for second-generation IGRA. 
Interpretation 
6 
Currently-available IGRAs lack sufficient accuracy for diagnostic evaluation of suspected TB. 
Second-generation tests, however, may have sufficiently high sensitivity, low negative LR and 
correspondingly high negative PV in low-incidence settings to facilitate prompt rule-out of TB. 
Funding 























Prompt diagnosis and treatment of active tuberculosis (TB) are essential for optimal patient 
outcomes and preventing onward transmission in the community and healthcare facilities.1 
However, diagnostic assessment of suspected TB can be lengthy, costly and burdensome for 
patients and healthcare systems,2 often resulting in significant delays in diagnosis and treatment 
of other diseases in cases where suspected TB is eventually ruled out. Improving and 
accelerating diagnostic evaluation thus remains a clinical and public health priority in high-
income, low-incidence countries, as well as high-burden regions. Recently, great advances in 
molecular diagnostics, such as GeneXpert (Cepheid Inc, Sunnyvale, CA, USA), have improved 
the speed and accuracy of microbiologic diagnosis and enabled prediction of antibiotic 
susceptibility.3 However, whilst such tests have high specificity (which is important for ‘rule-
in’), they have insufficient sensitivity to rule out TB and require clinical specimens from 
anatomical disease sites, often requiring resource-intensive invasive procedures.4 A blood test 
of high diagnostic sensitivity could help to promptly (e.g. in 24h) triage patients at clinical 
presentation (Appendix: Supplementary Panel, page 1); this would address a major unmet 
clinical need and has been prioritised by the World Health Organisation (WHO).5 Given the 
paucibacillary nature of most cases of culture-negative TB, such a test would likely be based 
on measurement of immune responses to M. tuberculosis (Mtb) rather than direct detection of 
the bacteria or nucleic acids.  
Interferon-gamma release-assays (IGRAs) are regulatory-approved immune-based blood tests 
for detecting Mtb infection. By measuring T-cell responses to two strongly immunogenic but 
highly specific Mtb antigens (ESAT-6 and CFP-10), they are not confounded by prior Bacillus 
Calmette-Guérin (BCG) vaccination and provide higher diagnostic specificity than the 
tuberculin skin test (TST).6 Since Mtb infection is a pre-requisite for TB disease, a negative 
IGRA result could potentially rule-out a diagnosis of TB disease (i.e. exclude TB from the 
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differential diagnosis), though prior evidence suggests the sensitivity of current IGRAs may be 
insufficient to fulfil this triage function.1,7–9  
Although established as the new standard-of-care for diagnosing latent TB infection (LTBI), 
IGRAs are currently not recommended in diagnosis of active TB other than in specific 
scenarios, such as paediatric TB, with caveats around interpretation and level of expertise 
required.10,11 However, development of definitive recommendations has been hindered by a 
lack of robust and informative evidence. Most studies of diagnostic accuracy of IGRAs in 
active TB to date are retrospective reviews of hospital records and TB registry data or small-
scale case-control studies, typically not representative of the heterogeneous patient population 
seen in real-life clinical practice. Although one large prospective cohort study embedded in 
routine practice and including head-to-head comparison of T-SPOT.TB and QFT-GIT was 
recently published, this was in a high TB-incidence setting.12 Prospective cohort studies 
conducted in low-incidence settings have been substantially smaller.1,8 
Given the shortfalls associated with available TB diagnostics, IGRAs continue to be used 
widely in clinical practice in the UK, albeit resulting in complexities and challenges in 
interpretation of results.11 A large-scale prospective head-to-head comparison of diagnostic 
performance of IGRAs in routine practice is therefore required to conclusively define what, if 
any, clinical role they have in diagnosis of active TB, allowing development of evidence-based 
and authoritative recommendations in this setting. 
Discovery of other highly-specific Mtb antigens as strongly immunogenic as ESAT-6 and CFP-
10 presents an opportunity to develop second-generation IGRAs of higher sensitivity.13,14 
Furthermore, they may allow development of an ‘ESAT-6-free’ IGRA for application in 
populations vaccinated with new ESAT-6-based TB vaccines, as previously described.15 
Studies suggest adaptation of existing IGRAs with these novel antigens is possible,1,14,16 but 
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no large-scale prospective clinical evaluation of this novel approach has been conducted in 
routine practice in a low TB-incidence setting.  
We therefore sought to evaluate the clinical utility of existing IGRAs, T-SPOT.TB (Oxford 
Immunotec plc, Abingdon, UK) and Quantiferon-Gold In-tube (QFT-GIT; Qiagen NV), and 
second-generation IGRAs in patients presenting with suspected TB in UK clinical practice.    
 
METHODS  
We conducted a prospective, multicentre, cohort study in routine clinical practice to determine 
the diagnostic accuracy of commercially-available and second-generation IGRAs in active TB. 
A within-patient design was used to compare test accuracy by performing all IGRAs on blood 
samples from each study participant, with the presence or absence of active TB verified using 
a composite reference standard (Table 1).1 This design minimises between-patient variability. 
The study was approved by Camden and Islington National Research Ethics Committee 
(11/H0722/8). The study protocol is available at https://njl-admin.nihr.ac.uk/document 
/download/2006627, and a STARD checklist is provided in the Appendix (Supplementary 
Checklist, pages 2-3). 
Study participants 
Adult inpatients and outpatients presenting with suspected active TB (based on signs and 
symptoms assessed by the attending hospital clinician) were consecutively enrolled from ten 
National Health Service (NHS) hospitals in five UK cities (London, Slough, Oxford, Leicester 
and Birmingham). Patients were enrolled at presentation to infectious disease and respiratory 
medicine secondary care services, before a final diagnosis was made, and a wide spectrum of 
pre-test probabilities for active TB were included. Exclusion criteria were limited to age <16y 
and inability/unwillingness to provide informed consent. Centres were selected to ensure the 
population was representative of ethnic mix and range of co-morbidities.  
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Participant enrolment and follow-up  
Participants were first seen by research nurses at enrolment. Following consent, a baseline 
blood sample was drawn and data collected in a case report form on the demographics and 
medical history of the participant, and investigations performed in their routine diagnostic 
work-up. Participants were followed up two and six months thereafter with data collected on 
any subsequent investigations, test results and clinical diagnoses, and response to TB treatment 
if initiated. Patients with a definitive non-TB diagnosis who were discharged from routine care 
were not required to attend follow-up visits but, where necessary, data were collected from 
hospital records up to 12 months after enrolment to identify final diagnoses made by hospital 
clinicians. 
Diagnosis and diagnostic categorisation  
Participants were investigated in routine practice under the direction of the infectious disease 
or respiratory medicine attending physician. After completion of follow-up in this routine 
hospital setting, participants’ final diagnoses were verified using a composite reference 
standard1 by a panel of ≥4 respiratory medicine and infectious disease clinicians specialising 
in TB. The panel assessed anonymised clinical data (patient demographics, medical history, 
TB symptoms, previous TB information, TB exposure history, current medication, human 
immunodeficiency virus (HIV) status, relevant clinical correspondence, test results during 
diagnosis and follow-up, and any other relevant clinical information) whilst blinded to all 
IGRA results (including IGRAs carried out as part of routine practice at recruiting sites). 
Diagnoses of all participants were categorised into the following groups, as previously defined1 
(Table 1): definite TB (category 1); highly-probable TB (category 2); clinically indeterminate 
(category 3); and non-TB (category 4). Category 4 participants were sub-divided based on risk 
factors for LTBI (Table 1). Final diagnoses and diagnostic categories were determined by 
consensus across the panel.  
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Laboratory procedures 
Blood samples (35ml) were collected into heparinised and QFT-GIT blood collection tubes 
from all participants at enrolment, before any diagnosis was made. QFT-GIT and T-SPOT.TB 
were carried out and interpreted in real-time at the TB Research Centre (Imperial College 
London) according to the manufacturer’s instructions, and as described in Whitworth et al.6 
The second-generation IGRA used the T-SPOT.TB platform and incorporated ESAT-6, CFP-
10 and Rv3615c; the ‘ESAT-6-free’ IGRA incorporated CFP-10, Rv3615c and Rv3879c. 
Further details on assay methods and interpretation of results are provided in the Appendix 
(Supplementary Methods, pages 4-5). Laboratory scientists performing study IGRAs were 
blinded to all clinical information, diagnoses and personal identifiers. 
Statistical Analyses 
The study was powered to detect a 10% difference in sensitivity between T-SPOT.TB and 
QFT-GIT, assuming a sensitivity of 85% for T-SPOT.TB and 75% for QFT-GIT.1,7–9 
Accounting for the paired nature of the data and assuming independence of errors,16 855 
patients (after loss-to-follow-up (LTFU)/withdrawal and missing/excluded index/reference test 
results) were required to detect this difference at the 5% significance level (two-tailed) with 
90% power, based on a predicted 40% prevalence of active TB in the study population. 
Sensitivity, specificity, positive and negative predictive values (PPV; NPV), and positive and 
negative likelihood ratios (PLR; NLR) for each test were calculated. Ninety-five percent 
confidence intervals (CIs) were calculated using the Wilson method for proportions18,19 and the 
method by Simel et al for LRs.20 All patients in diagnostic categories 1, 2 and 4 were included 
in analyses (Table 1); category 3 patients were reported but not included in analyses.  
Patients with indeterminate IGRA or borderline TSPOT-TB results were excluded from 
primary analyses, but included as test-positives in sensitivity analyses. Sensitivity analyses 
were also conducted to investigate the impact of (1) excluding category 2 patients on IGRA 
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sensitivity and (2) excluding category 4A-C patients on IGRA specificity.  To compare the 
accuracy of two IGRAs, we fitted separate generalized estimating equation (GEE) models for 
patients with and without active TB to estimate differences in sensitivity and specificity, 
respectively. This approach exploits the paired nature of the data whilst allowing use of all 
available data if test results were missing for either IGRA. We computed ratios of sensitivities 
(relative-sensitivity) and specificities (relative-specificity) from the GEE models using a post-
estimation procedure with CIs computed using the delta method. Analyses were performed 
using Stata, version 13.0 (Stata, College Station, Texas). 
Role of the funding source 
The study funder, the National Institute for Health Research (NIHR), played no role in study 
design, data collection, analysis or interpretation, or writing of the report. The corresponding 
author had full access to all data in the study and had final responsibility for the decision to 




Participant flow in the study is shown in Figure 1. Patients (n=1,060) with suspected active TB 
were consented and enrolled between 25 November 2011 and 31 August 2013. Those with a 
history of prior TB diagnosis (n=99) were excluded from analyses, as in previous studies.12 
Additionally, 116 patients were excluded for reasons provided in Figure 1, giving a final study 
population of 845 patients. 
Demographic & clinical characteristics  
Demographic and clinical characteristics for the final study population are shown in Table 2. 
The median age of the cohort was 38y (range 16-86y); 501/845 (59%) were male, and 412/845 
(48%) were of Indian Subcontinent origin. One or more co-morbidities were reported in 
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427/845 (51%) participants (Table 2). Medications at presentation are shown in the Appendix 
(Supplementary Table 1, page 6). The most common symptoms reported at presentation were 
cough, weight-loss and lethargy (Appendix: Supplementary Table 2, page 7). 
Diagnostic classification of patients 
Among the study cohort, 363/845 patients (43%) had a final diagnosis of active TB (Table 1); 
261/845 (31%) culture-confirmed (category 1), and 102/845 (12%) highly-probable (Category 
2). Of all active TB cases (categories 1 and 2), 129/363 (36%) were pulmonary, 189/363 (52%) 
were extra-pulmonary and 45/363 (12%) were both (Table 3); most 154/363 (42%) had lymph 
node involvement. Of Mtb isolates undergoing drug-susceptibility testing, 21/261 (6%) were 
drug-resistant and one was multi-drug-resistant. TB was excluded (category 4) in 439/845 
(52%) patients. These were sub-classified according to risk factors for LTBI or inactive TB 
into categories 4A-D in decreasing likelihood of having Mtb infection (Table 1).1 Most 
common non-TB diagnoses are listed in Table 3. Only 43/845 patients (5.1%) were classified 
as clinically indeterminate (category 3). 
Diagnostic accuracy of T-SPOT.TB and QFT-GIT  
T-SPOT.TB and QFT-GIT results were available for 809/845 (96%) and 820/845 (97%) study 
participants, respectively; 805/845 (95%) patients had data for both IGRAs. Diagnostic 
sensitivity, specificity, PPV, NPV, PLR and NLR are shown in Table 4, with a cross-tabulation 
of T-SPOT.TB and QFT-GIT results in patients with active TB and non-TB diagnoses provided 
in the Appendix (Supplementary Table 3, page 8). Sensitivity of T-SPOT.TB was 84.9% 
(95%CI 79.5-89.0%) for culture-confirmed TB and 81.4% (95%CI 76.6-85.3%) for all TB, 
giving an NPV of 84.7% (95%CI 80.6-87.9%) and NLR of 0.22 (95%CI 0.17-0.27) for all TB. 
Specificity was 86.2% (95%CI 82.3-89.4%) for all non-TB patients and 93.5% (95%CI 86.6-
97.0%) for cases with no risk factors for LTBI (category 4D). Sensitivity of QFT-GIT was 
70.6% (95%CI 64.4-76.1%) for culture-confirmed TB and 67.3% (95%CI 62.0-72.1%) for all 
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TB, giving an NPV of 74.0% (95%CI 69.5-78.0%) and NLR of 0.41 (95%CI 0.35-0.48) for all 
TB. Specificity was 80.4% (95%CI 76.1-84.1%) for all non-TB patients and 93.4% (95%CI 
86.4-96.9%) for cases with no risk factors for LTBI. Sensitivity and specificity of T-SPOT.TB 
were superior to QFT-GIT; relative sensitivity was 1.20 (95%CI 1.12-1.29) with p<0.0001, and 
relative specificity was 1.07 (95%CI 1.02-1.12) with p=0.004. 
Diagnostic accuracy of second-generation and ESAT-6-free IGRA 
Second-generation and ESAT-6-free IGRA results were available for 809/845 (96%) patients 
(Table 4). Sensitivity of second-generation IGRA was 94.0% (95%CI 90.0-96.4%) for culture-
confirmed TB and 89.2% (95%CI 85.2-92.2%) for all TB, giving an NPV of 90.0% (95%CI 
86.2-92.8%) and NLR of 0.13 (95%CI 0.10-0.19) for all TB. Specificity was 80.0% (95%CI 
75.6-83.8%) for all non-TB patients and 91.3% (95%CI 83.8-95.5%) for cases with no risk 
factors for LTBI. Sensitivity of ESAT-free IGRA was 93.4% (95%CI 89.2-96.0%) for culture-
confirmed TB and 88.0% (95%CI 83.8-91.2%) for all TB, giving an NPV of 89.2% (95%CI 
85.4-92.1) and NLR of 0.15 (95%CI 0.11-0.21) for all TB. Specificity was 79.6% (95%CI 
75.2-83.4%) for all non-TB patients and 90.3% (95%CI 82.6-94.8%) for cases with no risk 
factors for LTBI. Comparing second-generation IGRA with T-SPOT.TB, relative sensitivity 
was 1.08 (95%CI 1.04–1.11) with p<0.0001, and relative specificity was 0.94 (95%CI 0.91–
0.96) with p<0.0001. For ESAT-6-free IGRA versus T-SPOT.TB, relative sensitivity was 1.07 
(95%CI 1.03–1.10) with p=0.0002, and relative specificity was 0.93 (95%CI 0.90–0.96) with 
p<0.0001. A cross-tabulation of second-generation IGRA against T-SPOT.TB results and table 
of response magnitudes for each individual antigen are provided in the Appendix 
(Supplementary Tables 4 (page 9) and 5 (page 10) respectively). 
Test performance in key patient subgroups 
Of culture-confirmed TB cases with available smear microscopy results, 165/232 (71%) were 
smear-negative (57/165 with pulmonary TB, 80/165 with extra-pulmonary TB and 28/165 with 
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both). Sensitivities of T-SPOT.TB, QFT-GIT, second-generation IGRA and ESAT-6-free 
IGRA in this population were 85.9% (95%CI 79.2%-90.7%), 68.6% (95%CI 60.9%-75.4%), 
93.8% (95%CI 88.5%-96.7%) and 92.9% (95%CI 87.4%-96.1%), respectively. 
Among HIV-infected study participants, 25/135 (19%) had a final diagnosis of active TB and 
108/135 (80%) had TB excluded; 27/88 (31%) diabetic participants had a final diagnosis of TB 
(Table 2). Sensitivity and specificity of all IGRAs for active TB in patients with HIV-infection 
and diabetes are shown in the Appendix (Supplementary Tables 6 (page 11) and 7 (page 12), 
respectively).  
Indeterminate and borderline results 
There was a trend towards a higher indeterminate rate for QFT-GIT (79/820; 9.6%) than 
T-SPOT.TB (57/809; 7.0%; p=0.07), and rates for QFT-GIT were higher than second-
generation IGRA (55/809; 6.8%; p=0.04) and ESAT-6-free IGRA (55/809; 6.8%; p=0.04). 
Most indeterminate results occurred in non-TB patients (Appendix: Supplementary Tables 3 
(page 8) and 4 (page 9)). T-SPOT.TB results were borderline in 17/345 (4.9%) patients with 
active TB and 16/423 (3.8%) with non-TB diagnoses. Lowering the cut-off of T-SPOT.TB 
from eight to five SFCs (thereby scoring all borderline results as positive) did not improve 
diagnostic performance of T-SPOT.TB or either of the second-generation IGRAs, giving only 
a marginal increase in sensitivity at the cost of a decrease in specificity (Supplementary Table 
8; page 13). Scoring both indeterminate and borderline results as positives also did not affect 
test performance in sensitivity analyses (Table 4, footnote f).  
 
DISCUSSION  
This is the largest prospective cohort study embedded in real-life clinical practice to assess and 
compare the role of IGRAs in the evaluation of suspected pulmonary and extrapulmonary TB 
in a low TB-incidence setting. Although T-SPOT.TB had significantly higher sensitivity than 
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QFT-GIT, neither assay had sufficient sensitivity or NPV to rule out a diagnosis of active TB. 
In contrast, the second-generation IGRA, incorporating Rv3615c alongside ESAT-6 and CFP-
10, had significantly higher diagnostic sensitivity than T-SPOT.TB and QFT-GIT. 
Interestingly, and reflecting common practice despite the absence of good evidence or 
guidelines supporting use of IGRAs in this setting, 35% of study patients, distributed across 
the recruiting sites, had IGRAs performed as part of their routine diagnostic work-up for active 
TB (data not shown). 
The NLR of 0.13 for second-generation IGRA means a negative test result would reduce the 
odds of TB post-test by a clinically-meaningful factor of 7.7-fold compared to pre-test. The 
NPV for all TB, including highly-probable cases, was 90% despite the 43% prevalence in this 
population presenting to urban infectious diseases and respiratory medicine services with 
suspected TB. Since our study was performed in routine clinical practice and encompassed the 
full, natural clinical spectrum of TB and non-TB diagnoses, the results are likely generalizable 
across clinical practice in high-income, low-incidence countries. Accordingly, in clinical 
settings with a low-to-moderate pre-test probability of TB, such as general medical inpatient 
and outpatient services or primary care, second-generation IGRA has sufficiently low NLR to 
almost rule out TB. For example, a negative test result would convert pre-test probabilities of 
20% and 10% to post-test probabilities of 3.1% and 1.4%, respectively. This would provide a 
useful prompt triage of patients on initial presentation, similar to the role played by other 
diagnostic tests of high sensitivity and limited specificity, such as serum D-dimer to triage 
patients with low-to-moderate suspicion of venous thromboembolism.21 To our knowledge, 
other currently-available tests for TB lack required diagnostic sensitivity to fulfil this role. 
Although Xpert MTB/RIF Ultra has shown diagnostic sensitivity of 88%, its sensitivity in 
smear-negative, culture-positive TB is only 63%3 (and sensitivity of Xpert even lower4), 
compared to 93.8% (CI 88.6%-96.7%) for second-generation IGRA in this diagnostically 
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challenging subgroup who frequently have paucibacillary disease. However, the very high 
specificity of molecular tests such as Xpert provides high PPV, enabling rule-in of active TB. 
Second-generation IGRA may thus play a complementary role to rapid molecular tests in the 
diagnostic work-up of suspected TB.  
Given that IGRAs are the standard-of-care for detecting LTBI,10,11 they will inevitably identify 
LTBI in cases where active TB has been excluded. Because most people with possible TB in 
low-burden countries are from ethnic groups with a high prevalence of LTBI,22 as in our study, 
the diagnostic specificity for active TB is low for all IGRAs, and would be lower still in high-
burden countries. The enhanced diagnostic sensitivity of the second-generation IGRA was 
accompanied by only a modest reduction in specificity to 80%, similar to QFT-GIT. Our study 
confirms that the low specificity and PLR of current and second-generation IGRAs mean that 
a positive result cannot rule in a diagnosis of TB. Interestingly, the specificity of all IGRAs 
increased to 90-93% in patients with active TB excluded and no risk factors for LTBI (Category 
4D). Thus, a positive IGRA result may help to keep a diagnosis of active TB in the differential 
diagnosis in populations with a very low prevalence of LTBI, which however is not usually the 
case in patient populations being assessed for possible TB. 
Two of the leading new TB vaccine candidates, Hybrid 1-IC3123 and H56:IC31,24 contain 
ESAT-6 and may induce conversion of IGRA results in vaccinated individuals. If these 
vaccines show protective efficacy in ongoing clinical trials and achieve licensure, ESAT-6-
containing IGRAs will give false-positive results in vaccinated persons who are not Mtb-
infected, analogous to false-positive TST results in Mtb-uninfected persons with prior BCG 
vaccination. Diagnostic accuracy of ESAT-6-free IGRA was very similar to second-generation 
IGRA and thus has potential to replace other IGRAs in populations immunised against TB with 
ESAT-6-based vaccines. 
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Two of the most important global risk factors for TB are HIV co-infection25 and diabetes,26 
both of which have been reported to adversely affect IGRA performance.27,28 Performance of 
current IGRAs in patients with HIV-infection and diabetes in this study was insufficient to be 
of value in the diagnosis of active TB. Performance appeared to be lower in HIV-infected and 
diabetic subgroups, but the small numbers of patients with TB in these subgroups precluded 
statistical comparisons. This was also the case for other types of immunosuppression associated 
with TB, such as chronic kidney disease and immunosuppressive medication. 
Strengths of our study include the rigorous case definitions, including six-months follow-up to 
confirm that a diagnosis of TB was excluded where a non-TB diagnosis was not made at 
presentation. For highly-probable TB, we used a composite reference standard1 that was 
applied by a panel of expert and experienced clinicians, blinded to IGRA results. Despite this 
stringent case definition, it is likely that a proportion of patients without TB were incorrectly 
categorised as having highly-probable TB, which would explain why all IGRAs had lower 
sensitivity for highly-probable TB than for all TB, which includes culture-confirmed cases. 
Thus, our estimates of diagnostic sensitivity for all TB, which includes highly-probable TB, 
are likely conservative. This highlights the significance of increased IGRA sensitivity in 
culture-confirmed TB (and the importance of including this sub-group in study analyses) as 
this is the only population in whom TB diagnoses are definitive.  
Our study has some limitations. First, it does not include children, in whom the unmet clinical 
need for improved diagnosis of TB is high. Second, the numbers of patients with risk-factors 
associated with immunosuppression that do (e.g. HIV-infection) or might (e.g. diabetes) affect 
test performance were modest, precluding clear conclusions about test performance in these 
subpopulations. Third, whilst blood collection and assays were performed strictly in 
accordance with manufacturers’ instructions, IGRAs were not performed in a routine 
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diagnostic service laboratory, and  re-testing of new samples was not performed in cases where 
initial results were indeterminate or borderline (as recommended by manufacturers). 
Although the QFT-GIT has been replaced by the QFT-GIT-Plus since our study was conducted, 
its diagnostic accuracy does not appear to be significantly better than QFT-GIT and there is no 
evidence it is as sensitive as T-SPOT.TB.29,30 Therefore, our conclusion that neither existing 
IGRA has a clinically useful role in the evaluation of suspected active TB is unaffected by 
availability of QFT-GIT-Plus. 
In conclusion, our study provides conclusive and generalizable evidence that existing IGRAs 
do not have a useful role as rule-in or rule-out tests in routine clinical practice. However, 
second-generation IGRAs have higher sensitivity and NPV which may help to rule out a 
diagnosis of TB in clinical settings with a low-to-moderate prevalence of TB.  
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Table 1: Pre-defined criteria for case definitions and diagnostic categories.1 
Diagnostic category Criteria Number of 
Patients 
1: Culture-confirmed TBa Microbiological culture of M. tuberculosis, AND 
suggestive clinical and radiological findings. 
261 
2: Highly-probable TBa Clinical and radiological features highly suggestive 
of TB unlikely to be caused by other disease, AND a 
decision to treat made by a clinician, AND 
appropriate response to therapy, AND histology 
supportive if available. 
102 
3: Clinically indeterminate Final diagnosis of TB neither highly-probable, nor 
reliably excluded. 
43 
4: Active TB excluded   
Sub-classification   
     4A: Inactive TB Stable CXR changes, AND TST positiveb (if done), 
AND bacteriologically negative (if done), AND no 
clinical evidence of active disease. 
7 
     4B:  One or more risk factors for 
TB exposurec, TST positiveb 
TST positiveb, AND bacteriologically negative (if 
done) AND no clinical evidence of active disease. 
48 
     4C: One or more risk factors for 
TB exposurec, TST negative 
History of TB exposure, AND TST negative (if 
done). 
267 
     4D: No risk factors for TB 
exposurec, TST negative 
No history of TB exposure, AND TST negative (if 
done) 
117 
Total  845 
CXR, chest radiograph; TB, tuberculosis; TST, tuberculin skin test. 
aMtb culture is the gold standard test for diagnosis of active TB. However, given that even culture does not detect 
all TB cases, our previously-validated reference standard includes a second category for culture-negative but 
highly-probable active TB diagnoses, made based on other available evidence.1 
bTST using Mantoux test with  threshold ≥15mm considered positive  
cRisk factors for TB exposure: recent exposure to active TB patient; born in country of high prevalence; or 









Table 2: Demographics and clinical characteristics. Column percentages for each characteristic are shown. 
 
Characteristic 

















Clinical setting, n (%)      
Outpatient  171 (65.5) 72 (70.6) 32 (74.4) 269 (61.3) 544 (64.4) 
Inpatient 90 (34.5) 30 (29.4) 11 (25.6) 170 (38.7) 301 (35.6) 
Median age (range), 
years 
32 (16–81) 36 (18–76) 38 (16–79) 44 (17–86) 38 (16–86) 
Male, n (%) 177 (67.8) 53 (52.0) 21 (48.8) 250 (56.9) 501 (59.3) 
Ethnic origin, n (%)      
Indian Subcontinent 167 (64.0) 61 (59.8) 16 (37.2) 168 (38.3) 412 (48.8) 
Black 50 (19.2) 22 (21.6) 10 (23.3) 102 (23.2) 184 (21.8) 
White 22 (8.4) 9 (8.8) 12 (27.9) 126 (28.7) 169 (20.0) 
Asian 16 (6.1) 6 (5.9) 5 (11.6) 14 (3.2) 41 (4.9) 
Middle Eastern 4 (1.5) 0 0 12 (2.7) 16 (1.9) 
Mixed 1 (0.4) 4 (3.9) 0 8 (1.8) 13 (1.5) 
Hispanic 1 (0.4) 0 0 7 (1.6) 8 (0.9) 
Unknown 0 0 0 2 (0.5) 2 (0.2) 
Median years in UK 
(range) 
4.9 (0.1–52.9) 6.1 (0.3–59.7) 10.5 (0.4–56.9) 13.2 (0.0–60.3) 8.3 (0.0–60.3) 
Profession, n (%)a      
Paid employment 130 (49.8) 52 (51.0) 21 (48.8) 214 (48.7) 417 (49.4) 
Unemployed 62 (23.8) 24 (23.5) 16 (37.2) 164 (37.4) 266 (31.5) 
Student 50 (19.2) 13 (12.8) 3 (7.0) 26 (5.9) 92 (10.9) 
Healthcare/laboratory 
worker 
16 (6.1) 9 (8.8) 2 (4.7) 24 (5.5) 51 (6.0) 
Social/prison worker 1 (0.4) 1 (1.0) 0 2 (0.5) 4 (0.5) 
Sex worker 0 1 (1.0) 0 2 (0.5) 3 (0.4) 
Unknown 2 (0.8) 2 (2.0) 1 (2.3) 7 (1.6) 12 (1.4) 
Median height (range), m 1.7 (1.4–2.0) 1.7 (1.5–1.9) 1.6 (1.5–1.8) 1.7 (1.3–2.0) 1.7 (1.3–2.0) 
Median weight (range), 
kg 
63 (35–127) 64 (40–116) 71 (37–110) 68 (38–157) 65 (35–157) 
Median BMI (range) 22 (14–48) 22 (16–42) 24 (13–45) 24 (15–47) 23 (13–48) 
BCG vaccinated, n (%) 194 (74.3) 79 (77.5) 36 (83.7) 340 (77.4) 649 (76.8) 
BCG scar visible, n (%)      
Yes 172 (65.9) 72 (70.6) 29 (67.4) 283 (64.5) 556 (65.8) 
No  12 (4.6) 3 (2.9)  3 (7.0)  19 (4.3)  37 (4.4)  
Unknown  16 (6.1) 8 (7.8)  6 (14.0)  44 (10.0)  74 (8.8)  
28 
Missing  61 (23.4) 19 (18.6)  5 (11.6)  93 (21.2)  178 (21.1)  
Recent known TB 
contact, n (%) 
70 (26.8) 25 (24.5) 12 (27.9) 83 (18.9) 190 (22.5) 
Other pre-existing 
conditions/co-
morbidities, n (%)b 
     
None 169 (64.8) 61 (59.8) 19 (44.2) 169 (38.5) 418 (49.5) 
HIV-infected 13 (5.0) 12 (11.8) 2 (4.7) 108 (24.6) 135 (16.0) 
Diabetes 22 (8.4) 5 (4.9) 8 (18.6) 53 (12.1) 88 (10.4) 
Asthma 12 (4.6) 5 (4.9) 4 (9.3) 50 (11.4) 71 (8.4) 
Cancer 1 (0.4) 1 (1.0) 0 12 (2.7) 14 (1.7) 
Chronic/end stage 
kidney disease 
5 (1.9) 1 (1.0) 2 (4.7) 4 (0.9) 12 (1.4) 
Hepatitis C 1 (0.4) 1 (1.0) 0 10 (2.3) 12 (1.4) 
Hepatitis B 5 (1.9) 1 (1.0) 0 5 (1.1) 11 (1.3) 
Organ transplantation 0 0 0 2 (0.5) 2 (0.2) 
Sarcoidosis 1 (0.4) 0 0 0 1 (0.1) 
Other 74 (28.4) 37 (36.3) 20 (46.5) 228 (51.9) 359 (42.5) 
BMI, body mass index 
aSome patients had more than one profession. 


















Table 3: Final diagnoses of patients with and without active TB  
Confirmed or highly probably TB 
N = 363 
n (%) Active tuberculosis excludedb 
N = 439 
n (%) 
All TB 363 (100) Pneumonia 104 (23.7) 
Pulmonary  129 (35.5) Sarcoidosis 38 (8.7) 
Extrapulmonary  189 (52.1) Cancer 36 (8.2) 
Pulmonary and extrapulmonary  45 (12.4) Lower respiratory tract infection  23 (5.2) 
Site of diseasea Reactive lymphadenopathy  18 (4.1) 
Lungs 174 (47.9) Chest Infection 16 (3.6) 
Lymph node 154 (42.4) Exacerbation of asthma 14 (3.2) 
Pleura 26 (7.2) Upper respiratory tract infection 13 (3.0) 
Spine 16 (4.4) Non-tuberculosis mycobacterium infection 12 (2.7)  
Miliary TB (disseminated) 11 (3.0) Exacerbation of bronchiectasis 11 (2.5) 
Abdomen 9 (2.5) Exacerbation of COPD 8 (1.8) 
Pericardium 6 (1.7) Otherc 158 (36.0) 
Brain 6 (1.7)   
Musculoskeletal 5 (1.4)   
Chest wall 2 (0.6)   
Other 31 (8.5)   
COPD, Chronic obstructive pulmonary disease 
aSome patients had TB at multiple anatomical sites. 
bSome patients had multiple diagnoses. 

















T-SPOT.TBa,e,f QFT-GITa,e,f ESAT+ CFP10 + Rv3615ca,e,f CFP10 + Rv3615c + Rv3879ca,e,f 
n/N Estimate (95%CI) n/N Estimate (95%CI) n/N Estimate (95%CI) n/N Estimate (95%CI) 
Sensitivity for active TB         
All TB 253/311 81.4 (76.6–85.3) 220/327 67.3 (62.0–72.1) 273/306 89.2 (85.2–92.2) 263/299 88.0 (83.8–91.2) 
Culture-confirmed TB 185/218 84.9 (79.5–89.0) 163/231 70.6 (64.4–76.1) 203/216 94.0 (90.0–96.4) 197/211 93.4 (89.2–96.0) 
Highly-probable TBb 68/93 73.1 (63.3–81.1) 57/96 59.4 (49.4–68.7) 70/90 77.8 (68.2–85.1) 66/88 75.0 (65.0–82.9) 
Smear-positive TBc 45/55 81.8 (69.7–89.8) 42/56 75.0 (62.3–84.5) 48/51 94.1 (84.1–98.0) 47/50 94.0 (83.8–97.9) 
   Smear-negative TBc,d 169/206 82.0 (76.2–86.7) 148/222 66.7 (60.2–72.5) 183/207 88.4 (83.3–92.1) 176/202 87.1 (81.8–91.1) 
Pulmonary TB 79/105 75.2 (66.2–82.5) 79/115 68.7 (59.7–76.5) 88/100 88.0 (80.2–93.0) 85/97 87.6 (79.6–92.8) 
Extra-pulmonary TB 141/169 83.4 (77.1–88.3) 113/171 66.1 (58.7–72.8) 148/167 88.6 (82.9–92.6) 142/164 86.6 (80.5–91.0) 
Specificity for active TB         
Active TB excluded  319/370 86.2 (82.3–89.4) 304/378 80.4 (76.1–84.1) 296/370 80.0 (75.6–83.8) 296/372 79.6 (75.2–83.4) 
Active TB excluded, TST-
negative, no risk factors for LTBI 
87/93 93.5 (86.6–97.0) 85/91 93.4 (86.4–96.9) 84/92 91.3 (83.8–95.5) 84/93 90.3 (82.6–94.8) 
Predictive values for all TB         
Positive predictive value 253/304 83.2 (78.6–87.0) 220/294 74.8 (69.6–79.5) 273/347 78.7(74.1–82.7) 263/339 77.6 (72.8–81.7) 
Negative predictive value 319/377 84.6 (80.6–87.9) 304/411 74.0 (69.5–78.0) 296/329 90.0 (86.2–92.8) 296/332 89.2 (85.4–92.1) 
Likelihood ratios for all TB         
Positive likelihood ratio  5.90 (4.55–7.66)  3.44 (2.76–4.27)  4.46 (3.62–5.49)  4.31 (3.51–5.28) 
Negative likelihood ratio  0.22 (0.17–0.27)  0.41 (0.35–0.48)  0.13 (0.10–0.19)  0.15 (0.11–0.21) 
LTBI, latent tuberculosis infection; TST, tuberculin skin test. 
a25/845 QFT-GIT and 36/845 T-SPOT.TB and second-generation IGRA results were missing due to blood draw difficulties, samples being unsuitable for testing, or samples 
being destroyed for laboratory reasons. Missing results were spread across all diagnostic categories. 
31 
b’Highly-probable’ TB includes culture-negative TB cases plus 10 patients with a final diagnosis of TB who did not have Mtb culture performed. Sensitivity (95%CI) results 
for culture-negative TB alone were as follows: T-SPOT.TB – 69.9% (59.3–78.7); QFT-GIT – 57.1% (46.5–67.2); second-generation IGRA (ESAT-6, CFP-10, Rv3615c) – 
75.0% (64.5–83.2); ESAT-6-free IGRA (CFP-10, Rv3615c, Rv3879c) – 73.1% (62.3–81.7).   
c56/845 participants did not undergo smear microscopy. 
dAmong 165 patients who were smear-negative but culture-positive, 122/142 were T-SPOT.TB-positive; 105/153 were QFT-GIT-positive; 135/144 were positive in second-
generation IGRA and 131/141 were positive in ESAT-6-free IGRA. 
 eIndeterminate and borderline IGRA results were excluded from the analysis and thus also from data presented in this table. Numbers of indeterminate and borderline results 
for T-SPOT.TB/QFT-GIT and second-generation IGRA are presented in the Appendix (Supplementary Tables 3 (page5) and 4 (page 6), respectively).  
fWhen indeterminate and borderline results were included as test positives in sensitivity analyses (positive on the basis that such a result could not exclude a TB diagnosis), 
sensitivity (95%CI) results for all TB were as follows: T-SPOT.TB – 83.2% (78.9-86.8); QFT-GIT – 69.7% (64.7–74.2); second-generation IGRA (ESAT-6, CFP-10, Rv3615c) 
– 90.4% (86.9–93.1); ESAT-6-free IGRA (CFP-10, Rv3615c, Rv3879c) – 89.6% (85.9–92.4).   
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Figure 1: Study flow diagram of patients with suspected active TB 




Patients with suspected 
TB recruited from 10 sites 
N = 1,060 
Eligible for analyses 
N= 845 
Active TB excluded  
N = 439 
Clinically intermediate 
N = 43 
Highly probable TB  
N = 102 
Culture confirmed TB 
N = 261 
T-SPOT.TB: N = 246 
QFT-GIT: N = 252 
T-SPOT.TB: N = 423 
QFT-GIT: N = 425 
T-SPOT.TB: N = 41 
QFT-GIT: N = 42 
T-SPOT.TB: N = 99 
QFT-GIT:  N = 101 
Reasons for exclusion 
Previous TB diagnosis: N = 99a 
Exclusion by investigators: N = 66b 
Loss to follow-up: N = 39 
Withdrawal of consent: N = 8 
Death: N = 3 
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aPatients with previously diagnosed TB were excluded from analyses because IGRA results cannot be reliably interpreted in previously treated patients. The decision to 
exclude was taken by the expert diagnostic panel and study management group in consultation with the independent Study Steering Committee before unblinding of IGRA 
and next-generation IGRA results.  
bUpon advice from the Study Steering Committee, and following consultation between the study management group and data management groups, 66 patients were excluded 
from analyses. Patients recruited from one study site (n = 40) were excluded because they all had diagnoses of confirmed or highly-probable TB (categories 1 and 2) due an 
error of implementation of recruitment criteria at this site, i.e. the natural spectrum of patients with suspected TB was not being recruited. A further subset of patients (n = 26) 
were, upon review, considered by the expert diagnostic panel to be ineligible (before unblinding IGRA results) on the basis that they were being investigated for TB (due to an 
incidental abnormal chest x-ray, known contact with active TB, or screening for anti-TNF treatment), but did not present with symptoms or signs suggestive of TB.   
 
 
 
 
 
 
